AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank

Berenberg has issued a 'buy' rating for AstraZeneca (AZN), raising its 2030 revenue forecast to nearly $79 billion, asserting the market is not fully pricing in the potential of its late-stage pipeline. The bank highlights promising data from camizestrant, Enhertu, and baxdrostat as key growth drivers, projecting improved profitability and cash flow. Berenberg's £142 price target implies a 37% upside from current levels, noting AZN's attractive valuation relative to peers despite its strong growth prospects.

Analysis

According to a recent analyst update from Berenberg, AstraZeneca's (LSE:AZN) current market valuation fails to fully incorporate the potential of its late-stage drug pipeline. The bank has increased its 2030 revenue forecast for the pharmaceutical giant to nearly $79 billion, closely approaching the company's own $80 billion guidance. This optimistic outlook is underpinned by positive developments in key assets, including a 15% valuation increase for the breast cancer treatment camizestrant, alongside strong results from Enhertu and the new blood pressure medication baxdrostat. Beyond top-line growth, the analysis highlights improving profitability and cash flow, complemented by a 2.3% dividend yield. Critically, the stock trades at a modest price-to-earnings ratio relative to its peers, suggesting a valuation disconnect. Berenberg has reiterated a 'buy' rating with a price target of £142, which represents a 37% premium to the current trading price of £103.32.

Key Decisions for Investors

• Investors may consider the 37% potential upside to Berenberg's £142 price target as a compelling rationale to evaluate long positions, based on the thesis of an undervalued pipeline.
• Monitor upcoming clinical trial data and regulatory announcements for key drugs such as camizestrant and baxdrostat, as these events are the primary catalysts underpinning the bank's revised revenue forecasts.
• For a comprehensive view, investors should benchmark AstraZeneca's price-to-earnings ratio against industry peers to validate the relative value argument, while also considering the 2.3% dividend yield as a component of total shareholder return.